Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Developing vaccines against epidemic-prone emerging infectious diseases.

Bernasconi V, Kristiansen PA, Whelan M, Román RG, Bettis A, Yimer SA, Gurry C, Andersen SR, Yeskey D, Mandi H, Kumar A, Holst J, Clark C, Cramer JP, Røttingen JA, Hattchet R, Saville M, Norheim G.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Nov 27. doi: 10.1007/s00103-019-03061-2. [Epub ahead of print] Review.

PMID:
31776599
2.

Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening.

Shilling H, Murray G, Brotherton JML, Hawkes D, Saville M, Sivertsen T, Chambers I, Roberts J, Farnsworth A, Garland SM, Hocking JS, Kaldor J, Guy R, Atchison S, Costa AM, Molano M, Machalek DA.

Vaccine. 2019 Nov 22. pii: S0264-410X(19)31542-7. doi: 10.1016/j.vaccine.2019.11.019. [Epub ahead of print]

PMID:
31767467
3.

The Identification of Potential Therapeutic Targets for Cutaneous Squamous Cell Carcinoma.

McHugh A, Fernandes K, Chinner N, Ibrahim AFM, Garg AK, Boag G, Hepburn LA, Proby CM, Leigh IM, Saville MK.

J Invest Dermatol. 2019 Nov 6. pii: S0022-202X(19)33384-6. doi: 10.1016/j.jid.2019.09.024. [Epub ahead of print]

4.

Evaluation of p16/Ki-67 dual stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer.

Toliman PJ, Phillips S, de Jong S, O'Neill T, Tan G, Brotherton JML, Saville M, Kaldor JM, Vallely AJ, Tabrizi SN.

Clin Microbiol Infect. 2019 Oct 22. pii: S1198-743X(19)30556-7. doi: 10.1016/j.cmi.2019.10.020. [Epub ahead of print]

PMID:
31654795
5.

Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study.

Tan JHJ, Malloy MJ, Thangamani R, Gertig D, Drennan KT, Wrede CD, Saville M, Quinn M.

Aust N Z J Obstet Gynaecol. 2019 Oct 3. doi: 10.1111/ajo.13047. [Epub ahead of print]

PMID:
31578727
6.

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases.

Blackman MA, Marchionni MA, Gilly J, Hepburn M, Innis BL, Barrett ADT, Kester KE, Mascola JR, Cummings JF, Monath TP, Cassetti MC, Kim JH, Saville M, Thomas SJ.

Vaccine. 2019 Oct 8;37(43):6248-6254. doi: 10.1016/j.vaccine.2019.08.061. Epub 2019 Sep 6.

PMID:
31500964
7.

A review of Lassa fever vaccine candidates.

Salami K, Gouglas D, Schmaljohn C, Saville M, Tornieporth N.

Curr Opin Virol. 2019 Aug;37:105-111. doi: 10.1016/j.coviro.2019.07.006. Epub 2019 Aug 28. Review.

PMID:
31472333
8.

Lessons from the renewal of the National Cervical Screening Program in Australia.

Smith M, Hammond I, Saville M.

Public Health Res Pract. 2019 Jul 31;29(2). pii: 2921914. doi: 10.17061/phrp2921914.

9.

Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.

Brotherton JM, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, Coulter KA, Couvee PW, Steel N, Ward GH, Saville M.

Papillomavirus Res. 2019 Dec;8:100177. doi: 10.1016/j.pvr.2019.100177. Epub 2019 Jul 15.

10.

Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

Velentzis LS, Smith MA, Simms KT, Lew JB, Hall M, Hughes S, Yuill S, Killen J, Keane A, Butler K, Darlington-Brown J, Hui H, Brotherton JML, Skinner R, Brand A, Roeske L, Heley S, Carter J, Bateson D, Frazer I, Garland SM, Guy R, Hammond I, Grogan P, Arbyn M, Castle PE, Saville M, Armstrong BK, Canfell K.

Gynecol Oncol. 2019 Mar;152(3):465-471. doi: 10.1016/j.ygyno.2018.12.019.

PMID:
30876490
11.

Age-specific HPV prevalence among 116,052 women in Australia's renewed cervical screening program: A new tool for monitoring vaccine impact.

Brotherton JM, Hawkes D, Sultana F, Malloy MJ, Machalek DA, Smith MA, Garland SM, Saville M.

Vaccine. 2019 Jan 14;37(3):412-416. doi: 10.1016/j.vaccine.2018.11.075. Epub 2018 Dec 11.

PMID:
30551987
12.

Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?

Sultana F, Winch K, Saville M, Brotherton JML.

Int J Cancer. 2019 Jun 15;144(12):2964-2971. doi: 10.1002/ijc.32050. Epub 2019 Jan 11.

PMID:
30536935
13.

Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.

Saville M, Sultana F, Malloy MJ, Velentzis LS, Caruana M, Ip ELO, Keung MHT, Canfell K, Brotherton JML, Hawkes D.

J Clin Microbiol. 2019 Jan 30;57(2). pii: e01239-18. doi: 10.1128/JCM.01239-18. Print 2019 Feb.

14.

Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea.

Toliman PJ, Kaldor JM, Badman SG, Gabuzzi J, Silim S, Kumbia A, Kombuk B, Kombati Z, Munnull G, Guy R, Vallely LM, Kelly-Hanku A, Wand H, Ryan C, Tan G, Brotherton J, Saville M, Mola GDL, Garland SM, Tabrizi SN, Vallely AJ.

Papillomavirus Res. 2018 Dec;6:70-76. doi: 10.1016/j.pvr.2018.10.009. Epub 2018 Nov 1.

15.

The projected timeframe until cervical cancer elimination in Australia: a modelling study.

Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K.

Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/S2468-2667(18)30183-X. Epub 2018 Oct 2.

16.

Should Cervical Cancer Screening be Performed Before the Age of 25 Years?

Moscicki AB, Perkins RB, Saville M, Brotherton JML.

J Low Genit Tract Dis. 2018 Oct;22(4):348-351. doi: 10.1097/LGT.0000000000000434. No abstract available.

17.

Evaluation of self-collected vaginal specimens for the detection of high-risk human papillomavirus infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting.

Toliman PJ, Kaldor JM, Badman SG, Phillips S, Tan G, Brotherton JML, Saville M, Vallely AJ, Tabrizi SN.

Clin Microbiol Infect. 2019 Apr;25(4):496-503. doi: 10.1016/j.cmi.2018.05.025. Epub 2018 Jun 12.

PMID:
29906593
18.

'Lest we forget' as we move forward with cervical screening.

Saville M, McNally O.

Aust N Z J Obstet Gynaecol. 2018 Jun;58(3):265-266. doi: 10.1111/ajo.12813. No abstract available.

PMID:
29864221
19.

Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.

Hepburn LA, McHugh A, Fernandes K, Boag G, Proby CM, Leigh IM, Saville MK.

Oncotarget. 2018 May 1;9(33):23029-23046. doi: 10.18632/oncotarget.25196. eCollection 2018 May 1.

20.

Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.

McHugh A, Fernandes K, South AP, Mellerio JE, Salas-Alanís JC, Proby CM, Leigh IM, Saville MK.

Oncotarget. 2018 Apr 17;9(29):20265-20281. doi: 10.18632/oncotarget.24750. eCollection 2018 Apr 17.

21.

Self-collection for under-screened women in a National Cervical Screening Program: pilot study.

Saville M, Hawkes D, Mclachlan E, Anderson S, Arabena K.

Curr Oncol. 2018 Feb;25(1):e27-e32. doi: 10.3747/co.25.3915. Epub 2018 Feb 28.

22.

Completing the cervical screening pathway: Factors that facilitate the increase of self-collection uptake among under-screened and never-screened women, an Australian pilot study.

McLachlan E, Anderson S, Hawkes D, Saville M, Arabena K.

Curr Oncol. 2018 Feb;25(1):e17-e26. doi: 10.3747/co.25.3916. Epub 2018 Feb 28.

23.

Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.

Hall MT, Simms KT, Lew JB, Smith MA, Saville M, Canfell K.

PLoS One. 2018 Feb 14;13(2):e0185332. doi: 10.1371/journal.pone.0185332. eCollection 2018.

24.

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Canfell K, Saville M, Caruana M, Gebski V, Darlington-Brown J, Brotherton J, Heley S, Castle PE.

BMJ Open. 2018 Jan 26;8(1):e016700. doi: 10.1136/bmjopen-2017-016700. Erratum in: BMJ Open. 2018 Mar 8;8(3):e016700corr1.

25.

Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs.

Smith MA, Brotherton JML, Hammond IG, Anderson L, Simms KT, Saville M, Canfell K.

J Am Soc Cytopathol. 2018 Nov - Dec;7(6):336-338. doi: 10.1016/j.jasc.2018.08.002. Epub 2018 Oct 3. No abstract available.

PMID:
31043305
26.

Cost-effectiveness estimates: the need for complete reporting - Authors' reply.

Lew JB, Simms KT, Smith MA, Saville M, Hammond I, Canfell K.

Lancet Public Health. 2017 May;2(5):e212. doi: 10.1016/S2468-2667(17)30076-2. Epub 2017 Apr 28. No abstract available.

27.

Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.

Lew JB, St John DJB, Xu XM, Greuter MJE, Caruana M, Cenin DR, He E, Saville M, Grogan P, Coupé VMH, Canfell K.

Lancet Public Health. 2017 Jul;2(7):e331-e340. doi: 10.1016/S2468-2667(17)30105-6. Epub 2017 Jun 26.

28.

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.

Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, Hammond I, Canfell K.

Lancet Public Health. 2017 Feb;2(2):e96-e107. doi: 10.1016/S2468-2667(17)30007-5. Epub 2017 Feb 7.

29.

Not all HPV nucleic acid tests are equal: only those calibrated to detect high grade lesions matter for cervical screening.

Hawkes D, Brotherton JML, Saville M.

Clin Microbiol Infect. 2018 Apr;24(4):436-437. doi: 10.1016/j.cmi.2017.10.023. Epub 2017 Dec 6. No abstract available.

30.

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

Canfell K, Caruana M, Gebski V, Darlington-Brown J, Heley S, Brotherton J, Gertig D, Jennett CJ, Farnsworth A, Tan J, Wrede CD, Castle PE, Saville M.

PLoS Med. 2017 Sep 19;14(9):e1002388. doi: 10.1371/journal.pmed.1002388. eCollection 2017 Sep.

31.

How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.

Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, Canfell K.

Int J Cancer. 2017 Dec 15;141(12):2410-2422. doi: 10.1002/ijc.30926. Epub 2017 Oct 5.

32.

A new era for cervical screening in Australia: Watch this space!

Hammond I, Canfell K, Saville M.

Aust N Z J Obstet Gynaecol. 2017 Oct;57(5):499-501. doi: 10.1111/ajo.12669. Epub 2017 Aug 2. No abstract available.

PMID:
28766704
33.

Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.

Brotherton JML, Tabrizi SN, Phillips S, Pyman J, Cornall AM, Lambie N, Anderson L, Cummings M, Payton D, Scurry JP, Newman M, Sharma R, Saville M, Garland SM.

Int J Cancer. 2017 Oct 15;141(8):1576-1584. doi: 10.1002/ijc.30871. Epub 2017 Jul 14.

34.

Biological and Behavioral Factors Associated With Positive Chlamydia Retests.

Smith KS, Guy R, Danielewski J, Tabrizi SN, Fairley CK, McNulty AM, Rawlinson W, Saville M, Garland SM, Donovan B, Kaldor JM, Hocking JS; REACT investigators.

Sex Transm Dis. 2017 Jul;44(7):417-422. doi: 10.1097/OLQ.0000000000000616.

PMID:
28608791
35.

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.

Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, Hu B, Saville M, Chansinghakul D, Noriega F, Plennevaux E.

Hum Vaccin Immunother. 2017 Sep 2;13(9):2004-2016. doi: 10.1080/21645515.2017.1333211. Epub 2017 Jun 9.

36.

HPV vaccine coverage is increasing in Australia.

Brotherton JM, Winch KL, Bicknell L, Chappell G, Saville M.

Med J Aust. 2017 Apr 3;206(6):262. No abstract available.

PMID:
28359009
37.

Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.

Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K.

PLoS One. 2017 Jan 17;12(1):e0163509. doi: 10.1371/journal.pone.0163509. eCollection 2017.

38.

Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.

Harenberg A, de Montfort A, Jantet-Blaudez F, Bonaparte M, Boudet F, Saville M, Jackson N, Guy B.

PLoS Negl Trop Dis. 2016 Jul 26;10(7):e0004830. doi: 10.1371/journal.pntd.0004830. eCollection 2016 Jul.

39.

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.

Gailhardou S, Skipetrova A, Dayan GH, Jezorwski J, Saville M, Van der Vliet D, Wartel TA.

PLoS Negl Trop Dis. 2016 Jul 14;10(7):e0004821. doi: 10.1371/journal.pntd.0004821. eCollection 2016 Jul.

40.

Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.

Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, Saville M, Canfell K.

BMC Health Serv Res. 2016 Apr 26;16:147. doi: 10.1186/s12913-016-1375-9.

41.

Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction.

Plennevaux E, Sabchareon A, Limkittikul K, Chanthavanich P, Sirivichayakul C, Moureau A, Boaz M, Wartel TA, Saville M, Bouckenooghe A.

Vaccine. 2016 May 23;34(24):2707-12. doi: 10.1016/j.vaccine.2016.04.028. Epub 2016 Apr 18.

PMID:
27102820
42.

Dengue Vaccine in Regions of Endemic Disease.

Saville M, L'Azou M, Noriega F.

N Engl J Med. 2016 Apr 7;374(14):1388-9. doi: 10.1056/NEJMc1514451. No abstract available.

PMID:
27050219
43.

HPV vaccine impact in Australian women: ready for an HPV-based screening program.

Brotherton JM, Gertig DM, May C, Chappell G, Saville M.

Med J Aust. 2016 Mar 21;204(5):184-184e1. No abstract available.

PMID:
26985843
44.

Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia.

Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, Wrede CD, Heley S, Saville M, Gertig DM.

Int J Cancer. 2016 Jul 15;139(2):281-90. doi: 10.1002/ijc.30031. Epub 2016 Mar 10.

45.

The acceptability and cost of a home-based chlamydia retesting strategy: findings from the REACT randomised controlled trial.

Smith KS, Kaldor JM, Hocking JS, Jamil MS, McNulty AM, Read P, Bradshaw CS, Chen MY, Fairley CK, Wand H, Worthington K, Blake S, Knight V, Rawlinson W, Saville M, Tabrizi SN, Garland SM, Donovan B, Guy R.

BMC Public Health. 2016 Jan 28;16:83. doi: 10.1186/s12889-016-2727-4.

46.

Women's experience with home-based self-sampling for human papillomavirus testing.

Sultana F, Mullins R, English DR, Simpson JA, Drennan KT, Heley S, Wrede CD, Brotherton JM, Saville M, Gertig DM.

BMC Cancer. 2015 Nov 4;15:849. doi: 10.1186/s12885-015-1804-x.

47.

Vaccination Against Dengue: Challenges and Current Developments.

Guy B, Lang J, Saville M, Jackson N.

Annu Rev Med. 2016;67:387-404. doi: 10.1146/annurev-med-091014-090848. Epub 2015 Oct 23. Review.

PMID:
26515983
48.

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.

Guy B, Briand O, Lang J, Saville M, Jackson N.

Vaccine. 2015 Dec 10;33(50):7100-11. doi: 10.1016/j.vaccine.2015.09.108. Epub 2015 Oct 20. Review.

49.

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group.

N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.

50.

A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing.

Sultana F, Gertig DM, Wrede CD, English DR, Simpson JA, Drennan KT, Brotherton JM, Phillips G, Heley S, Castle PE, Saville M.

J Clin Virol. 2015 Aug;69:210-3. doi: 10.1016/j.jcv.2015.06.080. Epub 2015 Jun 19.

PMID:
26209409

Supplemental Content

Loading ...
Support Center